<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute myocardial infarction: Patients with diabetes mellitus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute myocardial infarction: Patients with diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute myocardial infarction: Patients with diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard W Nesto, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew A Cavender, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cardiovascular events related to atherosclerotic cardiovascular disease are a major cause of morbidity and mortality among patients with diabetes mellitus. Compared with patients without diabetes, those with diabetes are more likely to have coronary heart disease and more severe multivessel coronary artery disease when it occurs. As a result of these and other factors, patients with diabetes and coronary heart disease have worse outcomes, including lower rates of long-term survival when compared with patients without diabetes who have coronary heart disease. (See  <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">"Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus"</a>.)</p><p>With respect to acute myocardial infarction (MI), including ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI), in patients with diabetes, its treatment is broadly similar to that in those without diabetes. (See  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a>.)</p><p>This topic will focus on a number of specific issues that should be considered in diabetic patients. The majority of data discussed in this review are related to those patients with type 2 diabetes mellitus. However, despite a paucity of data in type 1 diabetes, the general principles of care appear to also be applicable to them. </p><p class="headingAnchor" id="H2"><span class="h1">RELATIONSHIP BETWEEN DIABETES AND MYOCARDIAL INFARCTION</span><span class="headingEndMark"> — </span>Diabetes is increasing in prevalence across the world and has increased from 108 million in 1980 to 422 million in 2014 [<a href="#rid1">1</a>]. Diabetes is underrecognized and it is estimated that approximately 5 percent of the population has undiagnosed diabetes [<a href="#rid2">2</a>]. While there have been overall reductions in the absolute number of acute myocardial infarctions in patients with diabetes given advances in medical therapy, these gains are threatened by the continued increase in the prevalence of diabetes [<a href="#rid3">3</a>].</p><p>It is not uncommon for the first diagnosis of diabetes to be made at the time of a MI. The incidence of newly diagnosed diabetes varies and has been found in approximately 5 percent of patients [<a href="#rid4">4,5</a>]. Other studies have found even higher prevalence of undiagnosed diabetes [<a href="#rid6">6</a>].</p><p>Similar to smoking, hypertension, and dyslipidemia, the high prevalence of diabetes in patients with acute MI relates to the fact that it is an independent risk factor for atherosclerotic heart disease. Diabetes has continued to be a significant independent risk factor for atherosclerotic heart disease. The importance of diabetes as a risk factor was illustrated in a 1998 study of the Finnish population that compared the seven-year incidence of MI in 1373 nondiabetics and 1059 patients with type 2 diabetes [<a href="#rid7">7</a>].</p><p>Patients with diabetes but no prior infarction had a similar risk of subsequent MI (20 and 19 percent, respectively) and coronary mortality (15 versus 16 percent) as nondiabetic patients with a prior MI. The risk of infarction was greatest in diabetics with a prior MI and lowest in nondiabetics without a prior MI (45 and 4 percent, respectively). While these data have led some to conclude that having diabetes increases a patient's risk of CHD events to a similar magnitude as patients with prior MI who do not have type 2 diabetes mellitus, the totality of and newer evidence does not support diabetes as a CHD equivalent. A 2009 meta-analysis found that those with diabetes but no history MI had a lower risk of cardiovascular events when compared with patients without diabetes who have had a prior MI (OR 0.56, 95% CI 0.53-0.60) [<a href="#rid8">8,9</a>].</p><p>In patients with acute MI, those with diabetes have significantly higher risk of subsequent mortality and future cardiovascular events [<a href="#rid10">10</a>]. Furthermore, there appears to be a <strong>graded</strong> rise in cardiovascular risk with increasing degree of hyperglycemia. In a community-based sample of elderly patients hospitalized with acute MI from 1994 to 1996, higher glucose levels were associated with higher risk of 30-day mortality in patients without known diabetes (glucose ≤110 mg/dL; range from glucose &gt;110 to 140 mg/dL: hazard ratio [HR] 1.17; 95% CI 1.11-1.24; to glucose ≥240 mg/dL: HR 1.87; 95% CI 1.75-2.00) [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">"Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus", section on 'CHD before diabetes'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Outcomes after myocardial infarction</span><span class="headingEndMark"> — </span>Outcomes after acute MI in patients with diabetes are worse than in patients without diabetes, particularly in women  (<a class="graphic graphic_figure graphicRef80251" href="/z/d/graphic/80251.html" rel="external">figure 1</a>) [<a href="#rid12">12-14</a>]. In the TIMI ACS trials from 1997 to 2006, 10,613 patients had diabetes (17 percent of the overall population). Diabetes was independently associated with higher mortality at 30 days after unstable angina/non-ST elevation MI (2.1 versus 1.1 percent; odds ratio [OR] 1.78; 95% CI 1.24-2.56) or STEMI (8.5 versus 5.4 percent; OR 1.40; 95% CI 1.24-1.57) [<a href="#rid15">15</a>].</p><p>Similar observations have been seen in other cohorts [<a href="#rid4">4,12,13,16-18</a>]. The reason for these associations are likely multifactorial and include higher burden of coronary artery disease, increased comorbidities such as renal disease, and increased acuity at the time of presentation.</p><p>In the TAMI trial, patients with diabetes were more likely to present in acute pulmonary edema than patients without diabetes (11 versus 4 percent in TAMI) [<a href="#rid12">12</a>]. The increased incidence of heart failure frequently occurs despite similar infarct sizes and left ventricular ejection fractions [<a href="#rid12">12,13,19</a>].</p><p>One or more of the following may contribute to the higher incidence of heart failure at the time of MI in diabetics:</p><p class="bulletIndent1"><span class="glyph">●</span>A greater extent of coronary disease (ie, more multivessel disease) which affects myocardial performance by limiting blood flow to noninfarcted myocardium [<a href="#rid12">12,20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intrinsic myocardial dysfunction. (See  <a class="medical medical_review" href="/z/d/html/3458.html" rel="external">"Heart failure in patients with diabetes mellitus: Epidemiology, pathophysiology, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased incidence of prior MI [<a href="#rid19">19,20</a>].</p><p></p><p>Diabetic patients also may have a higher risk of other complications, including arrhythmias, cardiogenic shock, heart failure, renal failure, and recurrent MI [<a href="#rid4">4,13,14,16,17</a>].</p><p class="headingAnchor" id="H860099366"><span class="h1">REPERFUSION</span><span class="headingEndMark"> — </span>Many patients with acute MI benefit from early reperfusion.</p><p class="headingAnchor" id="H7"><span class="h2">ST-elevation myocardial infarction</span><span class="headingEndMark"> — </span>Immediate coronary reperfusion is, in the absence of a contraindication, recommended in all patients with an acute ST-elevation MI (STEMI). This is usually achieved by primary percutaneous coronary intervention (PCI) or fibrinolytic therapy. Primary PCI is the preferred method for reperfusion after an acute ST-elevation MI since it produces better outcomes than thrombolysis. (See  <a class="medical medical_review" href="/z/d/html/72.html" rel="external">"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome"</a> and  <a class="medical medical_review" href="/z/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>.)</p><p class="headingAnchor" id="H282396414"><span class="h3">Primary percutaneous coronary intervention</span><span class="headingEndMark"> — </span>Patients with diabetes have better outcomes with primary PCI (percutaneous transluminal coronary angioplasty [PTCA] or stenting) than with fibrinolysis. The best data come from a meta-analysis of pooled patient data from 19 randomized trials that enrolled 6315 patients, 14 percent of whom had diabetes [<a href="#rid22">22</a>]. The following statistically significant findings were noted at 30 days:</p><p class="bulletIndent1"><span class="glyph">●</span>Mortality was lower after primary PCI than fibrinolysis (6.6 versus 12.4 percent; unadjusted OR 0.49, 95% CI 0.31-0.79).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Death or recurrent MI was reduced after primary PCI (9.6 versus 17.1 percent; unadjusted OR 0.52; 95% CI 0.35-0.77).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stroke was reduced after primary PCI (1.5 versus 3.7 percent; unadjusted OR 0.40; 95% CI 0.16-0.99).</p><p></p><p>The value of primary PCI with stenting compared to PTCA alone was evaluated in the CADILLAC trial in which 2082 patients with acute STEMI (almost 17 percent diabetic) were randomly assigned to PTCA alone, PTCA and abciximab, stenting alone, or stenting and abciximab; <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> was given to all patients initially and then continued in those who received a stent [<a href="#rid23">23</a>]. The outcomes were significantly better with stenting and the relative benefit was similar in patients with or without diabetes (OR 0.56 and 0.52, respectively). In the cohort with diabetes, the rate of target vessel revascularization at one year was higher in patients treated with PTCA when compared with coronary stenting (10.3 versus 22.4 percent, p = 0.004). There were no significant differences in the other endpoints including death, reinfarction, or stroke [<a href="#rid24">24</a>].</p><p>One possible contributor to the worse outcomes in diabetics is microvascular disease. This issue was addressed in a report of two substudies from the CADILLAC trial [<a href="#rid25">25</a>]. Two markers of tissue perfusion were evaluated: TIMI myocardial perfusion (blush) grade on angiography and ST segment resolution. (See  <a class="medical medical_review" href="/z/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction", section on 'Primary failure'</a>.)</p><p>The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Postprocedural TIMI flow grade 3 (normal flow) was attained in more than 95 percent of patients (including those with and without diabetes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with diabetes were significantly more likely to have a TIMI myocardial perfusion (or blush) grade of 0/1 after PCI (56 versus 47 percent in nondiabetics), indicating little or no tissue perfusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with diabetes were significantly more likely to have persistent ST-segment elevation (20 versus 8 percent), indicating a larger area with endangered perfusion.</p><p></p><p>These persistent abnormalities were associated with a trend toward increased mortality in patients with diabetes. Similar findings in diabetics (reduced myocardial blush grade and impaired ST-segment resolution after primary PCI) have also been noted in other studies [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Fibrinolytic therapy</span><span class="headingEndMark"> — </span>Patients with diabetes and ST-elevation myocardial infarction (STEMI) appear to derive the same or greater benefit (including mortality) from fibrinolytic therapy as patients without diabetes [<a href="#rid27">27</a>]. For patients who cannot receive timely PCI, fibrinolytic therapy should be considered.</p><p>While there has been a specific concern about the use of fibrinolytics with regard to the potential risk of intraocular hemorrhage in patients with diabetic retinopathy, we do not believe it is a major contraindication. Among 6011 patients with diabetes in the GUSTO-I trial, it was estimated that about 2000 had nonproliferative retinopathy and about 300 had proliferative retinopathy [<a href="#rid28">28</a>]. Only one patient had an ocular hemorrhage, which was an eyelid hematoma. Although the risk of ocular hemorrhage was not as completely evaluated in other major thrombolytic trials, an appreciable number of diabetics were included without reports of major intraocular bleeding [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1541631698"><span class="h2">Non-ST-elevation myocardial infarction</span><span class="headingEndMark"> — </span>In patients with an acute NSTEMI, an early invasive strategy in which patients go for coronary angiography with plans to proceed with revascularization (if amenable) within 48 hours of the index event has been shown to reduce cardiovascular events [<a href="#rid30">30</a>]. This benefit appears proportional to the risk of the patient. Given the increased risk associated with diabetes, this cohort warrants an early invasive strategy when presenting with NSTEMI. Coronary angiography, performed in the acute period following NSTEMI, demonstrates that the infarct-related artery is not occluded in 60 to 85 percent of cases.</p><p>However, because of improved long-term outcomes with revascularization, almost all patients with a NSTEMI are candidates for early angiography (performed within 4 to 48 hours after presentation) followed by revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) if appropriate. Given the higher prevalence of multivessel coronary artery disease in patients with diabetes, they are more likely to need CABG [<a href="#rid31">31</a>]. This topic will not be discussed further here since the presence or absence of diabetes does not influence decision making other than denoting the cohort of patients with diabetes as high risk in nature. (See  <a class="medical medical_review" href="/z/d/html/1581.html" rel="external">"Coronary artery revascularization in stable patients with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H316921044"><span class="h1">ANTICOAGULANT THERAPY</span><span class="headingEndMark"> — </span>Early anticoagulation remains a cornerstone of treatment for patients hospitalized with acute MI. The choice of anticoagulants is similar irrespective of the presence or absence of diabetes. Intravenous heparin is the preferred agent in patients undergoing PCI [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation"</a> and  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">ANTIPLATELET THERAPY</span><span class="headingEndMark"> — </span>All MI patients, including those with diabetes, should receive <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (see  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease", section on 'Summary and recommendations'</a>) and a P2Y<sub>12 </sub>receptor blocker<sub> </sub>as soon as possible after the diagnosis has been made. The choice of the P2Y<sub>12 </sub>receptor blocker<sub> </sub>depends on the reperfusion strategy. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Our approach to early DAPT'</a>.)</p><p>In every major trial which compared <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> to placebo or <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> to clopidogrel, outcomes in the subgroup of patients with diabetes were similar to the broad population of patients enrolled [<a href="#rid33">33-38</a>].</p><p>Patients with diabetes mellitus have increased platelet reactivity, with intensified adhesion, activation, and aggregation. This appears to be due to dysregulation of several signaling pathways secondary to changes at the receptor level (eg, increased expression) and abnormalities in intracellular downstream signaling [<a href="#rid39">39,40</a>]. These abnormalities may partially explain the higher risk of developing an acute coronary syndrome, as well as in the larger proportion of diabetes patients with inadequate response to antiplatelet agents (eg, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) compared to patients without diabetes. (See  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Diabetes mellitus'</a>.)</p><p>Since <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> is a pro-drug that may be metabolized into its active form via the liver, there is patient-level variation in platelet reactivity [<a href="#rid39">39,40</a>]. Patients with diabetes are more likely to have high platelet reactivity during treatment with clopidogrel. These patients are at increased risk of major adverse cardiovascular events [<a href="#rid41">41</a>]. Patients with diabetes benefit from more intensive antiplatelet therapy, and we choose <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> in most cases. (See  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Diabetes mellitus'</a>.)</p><p class="headingAnchor" id="H573551041"><span class="h2">Intravenous glycoprotein IIb/IIIa inhibitors</span><span class="headingEndMark"> — </span>For patients with diabetes and MI who receive early antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and a P2Y<sub>12</sub> inhibitor, we recommend not routinely using a GP IIb/IIIa inhibitor. In those patients undergoing PCI who have not been treated with a P2Y<sub>12</sub> inhibitor, intravenous <a class="drug drug_general" data-topicid="102219" href="/z/d/drug information/102219.html" rel="external">cangrelor</a> can be considered. GP IIb/IIIa inhibitor should be reserved for patients with thrombotic complications of PCI. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Intravenous agents'</a>.)</p><p class="headingAnchor" id="H4294847123"><span class="h1">SECONDARY PREVENTION</span><span class="headingEndMark"> — </span>Similar to the broad group of patients with acute MI, we employ multiple secondary preventive interventions in those with diabetes. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p class="headingAnchor" id="H3964127142"><span class="h2">Lipid lowering</span><span class="headingEndMark"> — </span>Patients with diabetes mellitus are considered to be at very high risk for subsequent coronary artery disease events. Aggressive low density lipoprotein cholesterol (LDL-C) lowering is beneficial in all patients with a prior MI. Patients should be started on high-intensity lipid-lowering therapy, such as with <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> 80 mg daily, while in the hospital. (See  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>Beta blocker therapy after MI reduces infarct size, the incidence of infarct extension, recurrent ischemia, reinfarction, and cardiac and sudden death mortality. The concern about the possibility of masking hypoglycemic symptoms or worsening glycemic control has made some physicians reluctant to prescribe beta blockers to patients with diabetes. However, these concerns have been overstated, and analysis of outcomes of diabetic subgroups in several postinfarction beta blocker trials has shown an overall benefit from the use of beta blockers that is at least equivalent to and may be greater than that seen in patients without diabetes [<a href="#rid42">42,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a>.)</p><p>The National Cooperative Cardiovascular Project reviewed the records of 45,308 patients 65 years of age or older, 26 percent of whom had diabetes [<a href="#rid44">44</a>]. After adjusting for potential confounders, use of beta blockers was associated with a lower one-year mortality rate for patients with both insulin and non-insulin-treated diabetes. The association between use of beta blockers and outcomes was similar to that seen in patients without diabetes. There was no association with an increased risk of readmission for diabetes-related complications. Despite these data, patients with diabetes were less likely to receive beta blockers when compared with patients without diabetes.</p><p class="headingAnchor" id="H11"><span class="h2">ACE inhibitors</span><span class="headingEndMark"> — </span>All patients with diabetes should be considered for an angiotensin converting enzyme (ACE) inhibitor or, if not tolerated, an angiotensin II receptor blocker early after the diagnosis of an MI. When given after an acute MI, ACE inhibitors reduce infarct size, limit ventricular remodeling, and reduce mortality.</p><p>They may be of particular benefit in patients with diabetes. Many patients with type 1 and 2 diabetes will be treated with an ACE inhibitor or angiotensin II receptor blocker for blood pressure control and risk mitigation even before their myocardial event. (See  <a class="medical medical_review" href="/z/d/html/74.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use"</a> and  <a class="medical medical_review" href="/z/d/html/71.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials", section on 'Effects in all patients'</a>.)</p><p>The GISSI-3 trial of patients with acute MI, which included 2790 patients with diabetes, found that six weeks of treatment with <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">lisinopril</a> reduced mortality (odds ratio 0.88; 95% CI 0.79-0.99) [<a href="#rid45">45</a>]. In the cohort with diabetes, six-month mortality was reduced (12.9 versus 16.1 percent)  (<a class="graphic graphic_figure graphicRef63118" href="/z/d/graphic/63118.html" rel="external">figure 2</a>) [<a href="#rid46">46</a>]. The benefit of ACE inhibition translated into 37 lives saved per 1000 treated patients, an effect that was higher than that observed in patients without diabetes.</p><p class="headingAnchor" id="H12"><span class="h2">Aldosterone antagonists</span><span class="headingEndMark"> — </span>We recommend an aldosterone receptor blocker to all patients with diabetes who meet the following criteria, which were derived from the EPHESUS trial of patients 3 to 14 days after acute MI [<a href="#rid47">47,48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Are receiving an ACE inhibitor and a beta blocker</p><p class="bulletIndent1"><span class="glyph">●</span>Have a left ventricular ejection fraction ≤40 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Have a serum creatinine ≤2.5 mg/dL (221 micromol/L) in men and ≤2.0 mg/dL (177 micromol/L) in women</p><p class="bulletIndent1"><span class="glyph">●</span>Have a serum potassium ≤5.0 mEq/L</p><p></p><p>The serum potassium must be monitored closely during treatment. Although uncommon, life-threatening hyperkalemia can occur due to the combination of aldosterone inhibition and reduced aldosterone secretion associated with ACE inhibitor therapy, and, in some patients, renal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a>.)</p><p class="headingAnchor" id="H2458214502"><span class="h2">Glycemic control</span><span class="headingEndMark"> — </span>The optimal target range of blood glucose in patients with acute MI is uncertain. In patients with acute MI who are critically ill (eg, receiving care in an intensive care unit), it is reasonable to use target blood glucose values appropriate for patients with critical illness; these target values are described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients", section on 'Target range of blood glucose'</a>.)</p><p>Patients with acute MI who are not critically ill should be treated for hyperglycemia according to standards for hospitalized patients, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1770.html" rel="external">"Management of diabetes mellitus in hospitalized patients", section on 'Noncritically ill'</a>.)</p><p>A number of trials addressed the effects of intensive insulin therapy or glycemic control in patients with acute MI, but they arrived at different conclusions and had flaws that limit their generalizability to practice [<a href="#rid49">49-51</a>].</p><p class="headingAnchor" id="H2748061894"><span class="h2">Other drugs</span></p><p class="headingAnchor" id="H727108010"><span class="h3">Sodium glucose-like co-transporter-2 inhibitors</span><span class="headingEndMark"> — </span>Sodium glucose-like co-transporter-2 (SGLT2) inhibitors including <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">canagliflozin</a> and <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a> reduce cardiovascular events by approximately 15 percent, largely in patients with prior cardiovascular events. The role of SGLT2 inhibitors in patients with diabetes is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p>SGLT2 inhibitors should be utilized in patients with diabetes following a myocardial infarction. There are no data available to support use during the acute event. Thus, these agents should be considered once patients are stabilized from their acute event, particularly in those patients in whom the risk of heart failure is elevated.</p><p class="headingAnchor" id="H3604201065"><span class="h3">GLP-1 receptor agonists</span><span class="headingEndMark"> — </span>Randomized clinical trials to establish cardiovascular safety have found that some glucagon-like peptide 1 receptor (GLP-1) agonists decrease cardiovascular events in patients with diabetes (see  <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"</a>). In a meta-analysis of seven trials, GLP-1 receptor agonists reduced cardiovascular death, MI, or stroke in patients with established coronary artery disease by 14 percent (HR 0.86, 95% CI 0.79-0.94). However, there are differences across the class with regard to the effects of an agent on cardiovascular events. GLP-1 receptor agonists have been shown to decrease cardiovascular events in the cohort of patients with established cardiovascular disease [<a href="#rid52">52</a>]. Similar to SGL2i, these agents should be considered once patients are stabilized from their acute event.</p><p class="headingAnchor" id="H971483529"><span class="h3">Metformin</span><span class="headingEndMark"> — </span>While <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> is first-line therapy for patients with diabetes, there have been no adequately powered randomized clinical trials to assess its benefit following an MI. In the GIPS III trial, there was no difference in left ventricular function at four months [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H1662273480"><span class="h3">Regulators of gene transcription</span><span class="headingEndMark"> — </span>Small molecule regulators of gene transcription, such as bromodomain and extraterminal (BET) proteins, may be involved in the pathogenesis of atherosclerosis (see  <a class="medical medical_review" href="/z/d/html/13603.html" rel="external">"Pathogenesis of atherosclerosis", section on 'Pathogenesis'</a>). The ability of apabetalone, a selective inhibitor of these proteins, to improve cardiovascular outcomes after ACS has been evaluated. In the BETonMACE randomized trial of 2425 ACS patients with diabetes and low high-density lipoprotein cholesterol, apabetalone did not significantly lower the rate of a composite of adverse cardiovascular outcomes during more than two years of follow-up (hazard ratio 0.82, 95% CI 0.645-1.04) [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Blood pressure control</span><span class="headingEndMark"> — </span>Hypertension should be aggressively treated in patients who have diabetes mellitus. The optimal goal blood pressure and choice of antihypertensive drugs in such patients are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Multifactorial risk factor reduction</span><span class="headingEndMark"> — </span>The benefits associated with multifactorial risk factor reduction (eg, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, blood pressure and glycemic control, and cessation of smoking) in patients with diabetes have been demonstrated in multiple studies [<a href="#rid55">55,56</a>]. Cardiac rehabilitation is indicated for patients with ACS and can be helpful in initiating lifestyle changes. The details of the protocol and overall results of this study are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Multifactorial risk factor reduction'</a> and  <a class="medical medical_review" href="/z/d/html/1552.html" rel="external">"Cardiac rehabilitation: Indications, efficacy, and safety in patients with coronary heart disease", section on 'Summary and recommendations'</a>.)</p><p class="headingAnchor" id="H762343191"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H17651228"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Coronary heart disease patients with diabetes have worse long-term survival than those without diabetes. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The treatment of myocardial infarction (MI) in patients with diabetes mellitus is largely similar to that in those without diabetes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with acute coronary syndrome (ACS) and diabetes should undergo early reperfusion. (See <a class="local">'Reperfusion'</a> above.)</p><p></p><p class="bulletIndent2">In patients with ST-elevation MI (STEMI), immediate percutaneous coronary intervention (PCI) is recommended. (See <a class="local">'ST-elevation myocardial infarction'</a> above.)</p><p></p><p class="bulletIndent2">In patients with NSTE-ACS, an early invasive strategy is recommended. The mode of revascularization, PCI or coronary artery bypass graft surgery, is dependent upon clinical variables including severity/burden of disease, anatomy, and patient characteristics. (See <a class="local">'Non-ST-elevation myocardial infarction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following ACS, patients should be treated with aggressive secondary prevention strategies. (See <a class="local">'Secondary prevention'</a> above.)</p><p></p><p class="bulletIndent2">This includes (but is not limited to) <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, high-dose statin therapy, beta blockers, renin-angiotensin-aldosterone system inhibitors, sodium-glucose co-transporter 2 inhibitors, and glucagon-like peptide-1 agonists in appropriate patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The optimal target range of blood glucose in patients with acute MI is uncertain. In patients with acute MI who are critically ill (eg, receiving care in an intensive care unit), it is reasonable to use target blood glucose values appropriate for patients with critical illness. These targets are described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients", section on 'Target range of blood glucose'</a>.)</p><p></p><p class="bulletIndent2">Patients with acute MI who are not critically ill should be treated for hyperglycemia, if present, according to standards for hospitalized patients, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1770.html" rel="external">"Management of diabetes mellitus in hospitalized patients", section on 'Noncritically ill'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387:1513.</a></li><li><a class="nounderline abstract_t">Cheng YJ, Kanaya AM, Araneta MRG, et al. Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016. JAMA 2019; 322:2389.</a></li><li><a class="nounderline abstract_t">Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014; 370:1514.</a></li><li><a class="nounderline abstract_t">Aguilar D, Solomon SD, Køber L, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110:1572.</a></li><li><a class="nounderline abstract_t">Shore S, Borgerding JA, Gylys-Colwell I, et al. Association between hyperglycemia at admission during hospitalization for acute myocardial infarction and subsequent diabetes: insights from the veterans administration cardiac care follow-up clinical study. Diabetes Care 2014; 37:409.</a></li><li><a class="nounderline abstract_t">Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359:2140.</a></li><li><a class="nounderline abstract_t">Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229.</a></li><li><a class="nounderline abstract_t">Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009; 26:142.</a></li><li><a class="nounderline abstract_t">Cavender MA, Steg PG, Smith SC Jr, et al. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 2015; 132:923.</a></li><li><a class="nounderline abstract_t">Cavender MA, Scirica BM, Bonaca MP, et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation 2015; 131:1047.</a></li><li><a class="nounderline abstract_t">Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005; 111:3078.</a></li><li><a class="nounderline abstract_t">Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993; 21:920.</a></li><li><a class="nounderline abstract_t">Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989; 14:49.</a></li><li><a class="nounderline abstract_t">Savage MP, Krolewski AS, Kenien GG, et al. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 1988; 62:665.</a></li><li><a class="nounderline abstract_t">Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298:765.</a></li><li><a class="nounderline abstract_t">Yudkin JS, Oswald GA. Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. Diabetes Care 1988; 11:351.</a></li><li><a class="nounderline abstract_t">Franklin K, Goldberg RJ, Spencer F, et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004; 164:1457.</a></li><li><a class="nounderline abstract_t">Zuanetti G, Latini R, Maggioni AP, et al. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993; 22:1788.</a></li><li><a class="nounderline abstract_t">Jaffe AS, Spadaro JJ, Schechtman K, et al. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108:31.</a></li><li><a class="nounderline abstract_t">Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:171.</a></li><li><a class="nounderline abstract_t">Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91:979.</a></li><li><a class="nounderline abstract_t">Timmer JR, Ottervanger JP, de Boer MJ, et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med 2007; 167:1353.</a></li><li><a class="nounderline abstract_t">Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.</a></li><li><a class="nounderline abstract_t">Stuckey TD, Stone GW, Cox DA, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol 2005; 95:1.</a></li><li><a class="nounderline abstract_t">Prasad A, Stone GW, Stuckey TD, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2005; 45:508.</a></li><li><a class="nounderline abstract_t">Timmer JR, van der Horst IC, de Luca G, et al. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 2005; 95:1375.</a></li><li><a class="nounderline abstract_t">Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349.</a></li><li><a class="nounderline abstract_t">Mahaffey KW, Granger CB, Toth CA, et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:1606.</a></li><li><a class="nounderline abstract_t">Ward H, Yudkin JS. Thrombolysis in patients with diabetes. BMJ 1995; 310:3.</a></li><li><a class="nounderline abstract_t">Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48:1319.</a></li><li><a class="nounderline abstract_t">O'Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol 2012; 60:106.</a></li><li><a class="nounderline abstract_t">Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 2014; 384:599.</a></li><li><a class="nounderline abstract_t">Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494.</a></li><li><a class="nounderline abstract_t">Franchi F, Rollini F, Aggarwal N, et al. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study. Circulation 2016; 134:780.</a></li><li><a class="nounderline abstract_t">Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045.</a></li><li><a class="nounderline abstract_t">James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010; 31:3006.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001.</a></li><li><a class="nounderline abstract_t">Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367:1297.</a></li><li><a class="nounderline abstract_t">Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011; 123:798.</a></li><li><a class="nounderline abstract_t">Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2:1282.</a></li><li><a class="nounderline abstract_t">Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50:1541.</a></li><li><a class="nounderline abstract_t">Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983; 6:285.</a></li><li><a class="nounderline abstract_t">Malmberg K, Herlitz J, Hjalmarson A, Rydén L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989; 10:423.</a></li><li><a class="nounderline abstract_t">Chen J, Marciniak TA, Radford MJ, et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol 1999; 34:1388.</a></li><li><a class="nounderline abstract_t">GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343:1115.</a></li><li><a class="nounderline abstract_t">Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96:4239.</a></li><li><a class="nounderline abstract_t">Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.</a></li><li><a class="nounderline abstract_t">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130:2354.</a></li><li><a class="nounderline abstract_t">Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314:1512.</a></li><li><a class="nounderline abstract_t">Malmberg K, Rydén L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26:650.</a></li><li><a class="nounderline abstract_t">Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006; 29:765.</a></li><li><a class="nounderline abstract_t">Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7:776.</a></li><li><a class="nounderline abstract_t">Lexis CP, van der Horst IC, Lipsic E, et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 2014; 311:1526.</a></li><li><a class="nounderline abstract_t">Ray KK, Nicholls SJ, Buhr KA, et al. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA 2020; 323:1565.</a></li><li><a class="nounderline abstract_t">Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580.</a></li><li><a class="nounderline abstract_t">Bittner V, Bertolet M, Barraza Felix R, et al. Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial. J Am Coll Cardiol 2015; 66:765.</a></li></ol></div><div id="topicVersionRevision">Topic 84 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27061677" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860047" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24738668" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Changes in diabetes-related complications in the United States, 1990-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364810" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24089537" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Association between hyperglycemia at admission during hospitalization for acute myocardial infarction and subsequent diabetes: insights from the veterans administration cardiac care follow-up clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12090978" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9673301" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19236616" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Is diabetes a coronary risk equivalent? Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26152709" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25681464" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939812" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450161" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2661630" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3421162" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699010" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diabetes and mortality following acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3402292" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249356" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8245329" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6731279" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207639" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7850985" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620527" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11919304" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15619385" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708696" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15904649" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2899772" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9385883" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7827552" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Thrombolysis in patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17010789" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22766336" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25131979" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11519503" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27559041" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717846" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ticagrelor versus clopidogrel in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20802246" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17982182" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prasugrel versus clopidogrel in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22920930" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343595" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diabetes and antiplatelet therapy in acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304032" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Platelet activation in type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17936152" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6347581" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Timolol treatment after myocardial infarction in diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2668003" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551683" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910229" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9416888" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668699" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25249586" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9169397" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728645" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567812" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31422062" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687169" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219359" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256393" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of a multifactorial intervention on mortality in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26271057" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
